


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
OCUL
Ocular Therapeutix Inc.
$15.41
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
OCUL Price Performance
$11.49 (+34.12%)
$12.44 (+23.87%)
$11.52 (+33.77%)
$8.56 (+80.02%)
OCUL has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

OCUL overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Loss widens YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
OCUL Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
OCUL Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is OCUL current stock price?
What are OCUL stock strengths?
What is OCUL Risk Level?
What is OCUL market cap and volume?
What is OCUL current Stock IQ?
Should I buy OCUL stock right now?
Is OCUL a Strong Buy right now?
What does a 'Strong Buy' rating mean for OCUL?
What does a 'Strong Sell' rating mean for OCUL?
What factors influence OCUL's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
OCUL
Ocular Therapeutix Inc.
Current Price
$15.41
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

OCUL Price Performance
$11.49 (+34.12%)
$12.44 (+23.87%)
$11.52 (+33.77%)
$8.56 (+80.02%)
OCUL Analysts Opinion
OCUL Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Loss widens YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
OCUL Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
OCUL Street Sentiment is extremely bullish and have positive views on the near-term outlook
OCUL has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
OCUL Stock IQ
OCUL Latest Analysis
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation. Fintel reports that on December 9 2025 Chardan Capital maintained coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy recommendation. Analyst Price Forecast Suggests 41.40% Upside
Today
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application. We recently published 10 Stocks Standing Tall Amid Market Fall. 6 Hit Record Highs. Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best performers on Monday. Ocular Therapeutix surged to a new four-year high on Monday after rallying for four consecutive days with investor sentiment bolstered by announcements that it would officially submit a new [….]
Tue Dec 9, 2025
Needham Reiterates Ocular Therapeutix (OCUL) Buy Recommendation. Fintel reports that on December 8 2025 Needham reiterated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy recommendation. Analyst Price Forecast Suggests 81.08% Upside
Tue Dec 9, 2025
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation. Fintel reports that on December 8 2025 HC Wainwright &. Co. maintained coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy recommendation. Analyst Price Forecast Suggests 81.08% Upside
Tue Dec 9, 2025
HC Wainwright & Co. Reiterates Ocular Therapeutix (OCUL) Buy Recommendation. Fintel reports that on November 25 2025 HC Wainwright &. Co. reiterated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy recommendation. Analyst Price Forecast Suggests 88.26% Upside
Tue Nov 25, 2025
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet. The consensus price target hints at an 82.5% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Thu Nov 20, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
OCUL Stock trends
OCUL Stock performance
OCUL Stock analysis
OCUL investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.